United Therapeutics (NASDAQ:UTHR) CFO Sells $209,609.40 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 364 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $575.85, for a total value of $209,609.40. Following the completion of the sale, the chief financial officer owned 18,996 shares of the company’s stock, valued at $10,938,846.60. The trade was a 1.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

James Edgemond also recently made the following trade(s):

• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total value of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total value of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total value of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total value of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $561.50, for a total value of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $593.17, for a total value of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Trading Down 1.0%

UTHR stock traded down $5.69 during midday trading on Friday, hitting $567.16. The company had a trading volume of 264,756 shares, compared to its average volume of 491,071. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $607.89. The stock’s 50 day moving average price is $534.64 and its 200 day moving average price is $493.24. The stock has a market cap of $24.86 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 1.63 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the company posted $6.19 earnings per share. The business’s revenue was up 7.4% on a year-over-year basis. Analysts predict that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. TD Cowen boosted their price objective on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Royal Bank Of Canada boosted their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Cantor Fitzgerald boosted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $601.50.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. AE Wealth Management LLC raised its holdings in shares of United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after acquiring an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC raised its holdings in shares of United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after acquiring an additional 2,975 shares in the last quarter. Optimize Financial Inc bought a new position in shares of United Therapeutics during the third quarter valued at approximately $444,000. Simplify Asset Management Inc. purchased a new stake in United Therapeutics in the third quarter worth $8,351,000. Finally, Merit Financial Group LLC grew its stake in United Therapeutics by 56.3% in the third quarter. Merit Financial Group LLC now owns 7,416 shares of the biotechnology company’s stock worth $3,109,000 after purchasing an additional 2,672 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.